ImmuPharma plc (LON:IMM – Get Free Report)’s stock price traded down 5.7% during trading on Thursday . The stock traded as low as GBX 4.20 ($0.05) and last traded at GBX 4.43 ($0.06). 4,153,455 shares changed hands during trading, a decline of 79% from the average session volume of 19,996,625 shares. The stock had previously closed at GBX 4.70 ($0.06).
ImmuPharma Stock Performance
The firm has a market capitalization of £16.58 million, a PE ratio of -6.74 and a beta of 1.53. The firm has a fifty day moving average of GBX 2.77 and a 200 day moving average of GBX 2.04.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Featured Stories
- Five stocks we like better than ImmuPharma
- 5 Top Rated Dividend Stocks to Consider
- NVIDIA’s Hidden AI Play: The Truth Behind Its WeRide Investment
- 3 REITs to Buy and Hold for the Long Term
- Up 50% in January, Twilio’s Pullback Is the Time to Buy
- Why Invest in High-Yield Dividend Stocks?
- Watch These 3 Stocks—High Short Interest and Big Upside Potential
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
